Timothy Kieffer
Hoofd Techniek/Wetenschap/O&O bij FRACTYL HEALTH, INC.
Vermogen: - $ op 30-04-2024
Profiel
Timothy Kieffer is currently the Chief Scientific Officer at Fractyl Health, Inc. He previously held the position of Chief Scientific Officer at ViaCyte, Inc. from 2021 to 2022.
Prior to his industry roles, he worked as a Professor at the University of British Columbia.
Dr. Kieffer obtained a doctorate degree from the University of British Columbia.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
FRACTYL HEALTH, INC.
-.--% | 15-03-2024 | 0 ( -.--% ) | - $ | 30-04-2024 |
Actieve functies van Timothy Kieffer
| Bedrijven | Functie | Begin |
|---|---|---|
| FRACTYL HEALTH, INC. | Hoofd Techniek/Wetenschap/O&O | 01-09-2023 |
Eerdere bekende functies van Timothy Kieffer
| Bedrijven | Functie | Einde |
|---|---|---|
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Hoofd Techniek/Wetenschap/O&O | 01-10-2022 |
| University of British Columbia | Corporate Officer/Principal | - |
Opleiding van Timothy Kieffer
| University of British Columbia | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| FRACTYL HEALTH, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
